CVKD · Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Inc Is A Late-Stage Biopharmaceutical Company Advancing Novel Therapies For Life-Threatening Immune And Thrombotic Conditions. Its Product Candidate, Cad-1005, Is A First-In-Class Selective 12-Lox Inhibitor Being Developed To Treat Heparin-Induced Thrombocytopenia (Hit), A Deadly Immune-Mediated Thrombotic Disorder. The Pipeline Includes Two Additional Clinical-Stage Assets: Tecarfarin And Frunexian. Tecarfarin Is An Oral Vitamin K Antagonist (Vka) Designed To Prevent Heart Attacks, Strokes, And Deaths Due To Blood Clots In Patients Requiring Chronic Anticoagulation. Frunexian Is A First-In-Class, Phase 2-Ready Intravenous Factor Xia Inhibitor Designed For Acute Care Settings Where Contact Activation Of Coagulation By Medical Devices Or Artificial Surfaces.